A detailed history of Sg Americas Securities, LLC transactions in Ideaya Biosciences, Inc. stock. As of the latest transaction made, Sg Americas Securities, LLC holds 3,397 shares of IDYA stock, worth $92,364. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,397
Previous 11,775 71.15%
Holding current value
$92,364
Previous $413,000 73.85%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 03, 2024

SELL
$30.37 - $43.05 $254,439 - $360,672
-8,378 Reduced 71.15%
3,397 $108,000
Q2 2024

Jul 12, 2024

BUY
$34.37 - $43.46 $325,552 - $411,653
9,472 Added 411.29%
11,775 $413,000
Q1 2024

May 06, 2024

BUY
$34.2 - $47.13 $78,762 - $108,540
2,303 New
2,303 $101,000
Q3 2023

Oct 13, 2023

BUY
$21.07 - $29.77 $442,996 - $625,914
21,025 New
21,025 $567,000
Q1 2023

Apr 28, 2023

BUY
$13.49 - $18.72 $50,466 - $70,031
3,741 Added 12.39%
33,940 $466,000
Q4 2022

Feb 02, 2023

BUY
$14.47 - $18.17 $205,691 - $258,286
14,215 Added 88.93%
30,199 $549,000
Q3 2022

Oct 31, 2022

SELL
$9.24 - $15.79 $82,162 - $140,404
-8,892 Reduced 35.75%
15,984 $238,000
Q2 2022

Jul 29, 2022

BUY
$8.28 - $13.88 $205,973 - $345,278
24,876 New
24,876 $343,000
Q1 2022

Apr 29, 2022

SELL
$11.18 - $24.02 $170,316 - $365,920
-15,234 Closed
0 $0
Q4 2021

Feb 07, 2022

SELL
$20.95 - $26.88 $175,980 - $225,792
-8,400 Reduced 35.54%
15,234 $360,000
Q3 2021

Nov 01, 2021

BUY
$17.26 - $27.08 $182,006 - $285,558
10,545 Added 80.56%
23,634 $602,000
Q2 2021

Aug 12, 2021

BUY
$17.76 - $24.83 $101,729 - $142,226
5,728 Added 77.82%
13,089 $275,000
Q1 2021

May 13, 2021

BUY
$13.48 - $23.77 $99,226 - $174,970
7,361 New
7,361 $173,000

Others Institutions Holding IDYA

About IDEAYA Biosciences, Inc.


  • Ticker IDYA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,067,700
  • Market Cap $1.31B
  • Description
  • IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinica...
More about IDYA
Track This Portfolio

Track Sg Americas Securities, LLC Portfolio

Follow Sg Americas Securities, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sg Americas Securities, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sg Americas Securities, LLC with notifications on news.